Balugrastim biosimilar - Jiangsu T-mab BioPharma
Alternative Names: GW-003Latest Information Update: 28 Oct 2018
At a glance
- Originator Jiangsu T-mab BioPharma
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Recombinant fusion proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists; Granulocyte stimulants; Haematopoiesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neutropenia
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for phase-I development in Neutropenia(In volunteers, Chemotherapy-induced) in China (SC, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Neutropenia(Chemotherapy-induced) in China (SC, Injection)
- 01 Mar 2016 Jiangsu T-Mab Biopharma initiates enrolment in a phase I trial in Neutropenia (Chemotherapy-induced) in China (SC) (NCT02725606)